Complications after radical prostatectomy: our experiences
Abstract
Background: Prostate carcinoma is one of the most important health problems of men’s population. Radical prostatectomy is the method of choice for treatment patients with localized disease and life expectancy of 10 or more years. Complications after radical prostatectomy are urine incontinence, erectile dysfunction, stricture on anastomosis and biochemical recurrence (rising PSA).
Methods: Retrospective analysis of complications after radical prostatectomy done at our department from 1998 to 2003.
Results: From 1998 to 2003 we performed a radical prostatectomy in 93 patients. 13 (14 %) patients presented with urine incontinence, 32 (34 %) with erectile dysfunction, 14 (15 %) with stricture and 26 (28 %) with biochemical failure.
Conclusions: Complications after radical prostatectomy on our department are comparable with those found in the literature. Patients with higher PSA level, higher Gleasson score and positive surgical margins are at greater risk of developing a recurrence.
Downloads
References
Ellis WJ, Lange PH. Prostate cancer. Endocrinol Metab Clin North Am 1994; 23: 809–24.
Register raka za Slovenijo. Incidenca raka v Sloveniji 2002. Ljubljana: Onkološki Inštitut Ljubljana; 2005.
Sandblom G, Varenhorst E. Incidence rate and management of prostate carcinoma. Biomed Pharmacother 2001; 55: 135–43.
Thiel R, Ackermann R. Avoiding complications of radical retropubic prostatectomy. Eur Urol 1997; 31 Suppl 3: 9–15.
Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P, et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int 2004; 93: 680–8.
European Network of Cancer Registries. Dosegljivo na: Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075–107.
Alivizatos G, Skolarikos A. Incontinence and erectile dysfunction following radical prostatectomy: a review. ScientificWorld J 2005; 5: 747–58.
Teloken C. Management of erectile dysfunction secondary to treatment for localized prostate cancer. Cancer Control 2001; 8: 540–5.
Moul JW, Mooneyhan RM, Kao TC, McLeod DG, Cruess DF. Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy. Prostate Cancer Prostatic Dis 1998; 1: 242–9.
Carroll P. Rising PSA after a radical treatment. Eur Urol 2001; 40 Suppl 2: 9–16.
Augustin H, Hammerer PG. Disease recurrence after radical prostatectomy. Contemporary diagnostic and therapeutical strategies. Minerva Urol Nefrol 2003; 55: 251–61.
Bott SR, Kirby RS. Avoidance and management of positive surgical margins before, during and after radical prostatectomy. Prostate Cancer Prostatic Dis 2002; 5: 252–63.
Altwein JE. Enhancing the efficacy of radical prostatectomy in locally advanced prostate cancer. Urol Int 1998; 60 Suppl 2: 2–10.
Downs TM, Kane CJ, Grossfeld GD, Meng MV, Carroll PR. Surgery for prostate cancer: rationale, technique and outcomes. Cancer Metastasis Rev 2002; 21: 29–44.
Rashid MH, Chaudhary UB. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 2004; 9: 295–301.
Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16–21.
Pound CR, Brawer MK, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 2001; 3: 72–84.Mcleod DG. Hormonal therapy: historical perspective to future directions. Urology 2003; 61 Suppl 1: 3–7.
Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007; 51: 306–14.
Adolfsson J. Health-related quality-of-life assessments in patients with advanced cancer of the prostate. Pharmacoeconomics 2003; 21: 241–7.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
